ALZN (alzamend.com) Gross Profit Margin

ALZN (Alzamend Neuro) - company brandmark

Alzamend Neuro, Inc. (ALZN) is a biotech company in early-stage Alzheimer's trials with zero revenue and a high cash burn rate. The gross profit margin trend clearly demonstrates a lack of commercial sales, while the 0.00 level records fresh values. Rising clinical trial costs hinder scaling and eliminate operating leverage. High barriers to entry and patent protection make this niche accessible only to the largest industry behemoths.

Alzamend (ALZN) Gross Profitability: for the period 07/04/2022 - 11/20/2026

Comprehensive metric breakdowns and analytics for Alzamend (ALZN)

Fundamental valuation:ALZN - alzamend.com
Signature product of Alzamend Neuro Inc.

Gross margin measures production efficiency by determining the profit share after deducting direct costs, serving as an indicator of the issuer's pricing power. Investors should evaluate gross margin deviations as a signal of operational fundamental stability and the business's ability to scale profitability. For Alzamend Neuro, Inc. (ALZN), patents for early-stage Alzheimer's disease therapy development minimize pricing pressure, protecting high margins.

Main competitors

Return on Gross Profit Biogen Corp|Return on Gross Profit NBIX|Regencell Corp (RGC) - Return on Sales by Gross Profit|Gross Margin AXSM|Return on Gross Profit ACADIA Pharmaceuticals ACAD|Gross Margin XENE (Xenon Pharmaceuticals Inc.)|VKTX (Viking Therapeutics, Inc.) - Gross Profitability Margin|SUPN - Gross Profitability|Catalyst Pharmaceuticals Inc (CPRX) - Return on Gross Profit|DNLI (Denali Corp) - Return on Gross Profit|Gross Profit Margin harmonybiosciences.com (HRMY)|Return on Gross Profit BHVN|Gross Margin Amylyx|Gross Margin TRVI|PRAX (Praxis Corp) - Gross Profit Rate|Gross Margin AVXL (anavex.com)|CBLL: Gross Return on Sales|PRTA - Gross Profitability|ALEC - Gross Margin|Annexon Inc. (ANNX) - Gross Profitability|Return on Gross Profit Omeros Corp|Return on Gross Profit NGNE|ACIU: Gross Profit Rate|Return on Gross Profit VYGR (Voyager Corp)|Return on Gross Profit Neumora NMRA|Gross Profitability Scilex Holding Company, Inc. SCLX|Gross Sales Margin Tevogen Bio Inc.|ACOG - Gross Profitability|Gross Sales Margin Cognition Therapeutics (CGTX)|IKT (Inhibikase Therapeutics) - Return on Gross Profit|Cassava Sciences Inc (SAVA) - Gross Margin|Return on Gross Profit ASRT|Gross Margin coyatherapeutics.com|Gross Margin VTGN|Ovid Therapeutics - Gross Return on Sales|Gross Margin ABOS (Acumen Pharmaceuticals, Inc)|CRVO - Return on Gross Profit|ATHE - Gross Profitability|Return on Sales by Gross Profit clene.com CLNN|PEPG: Gross Margin|Gross Return on Sales JUNS|RLMD (Relmada Corp) - Gross Margin|Annovis Bio Inc (ANVS) - Return on Sales by Gross Profit|Gross Profitability Grace Therapeutics, Inc. (GRCE)|AIFF (Firefly Neuro) - Gross Profit Rate|Gross Profitability Klotho Neurosciences KLTO|NRSN: Gross Return on Sales|RVPH: Return on Gross Profit|MTVA: Gross Profitability|NRXS (NeurAxis Inc) - Return on Gross Profit|Return on Gross Profit Helius Medical Technologies, Inc.|Gross Profitability Passage Bio Inc.|Gross Profit Margin bionomics.com.au NEUP|Gross Margin NERV|Gross Margin Athira Pharma Inc (ATHA)|Gross Margin ADXN (Addex Therapeutics Ltd.)|Return on Sales by Gross Profit Cyclerion Therapeutics (CYCN)|Protagenic - Gross Margin|Gross Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Gross Margin|Avenue Therapeutics Inc. (ATXI) - Gross Margin|BCLI (BrainStorm Cell Therapeutics Inc.) - Gross Margin|Gross Margin Cara Therapeutics Inc|Gross Profitability Chromocell Therapeutics (CHRO)|Gross Profit Ratio ELYM|Gross Profitability Intra-Cellular ITCI|LBPH: Gross Return on Sales|MRNS - Gross Profitability|NKGen Biotech, Inc. (NKGN) - Return on Gross Profit|neurobopharma.com (NRBO) - Gross Profitability|SAGE: Gross Profit Ratio|Gross Profitability Synaptogenix, Inc.|Gross Profitability TRVN|Gross Margin VIGL|Gross Margin anewmeds.com (WENA)|Gross Margin CERE (cerevel.com)